Navigation Links
BGI and GT Life Sciences, Inc. Report Genome Sequence of CHO-K1 and Provide New Insights into Optimization of Biopharmaceutical Protein Production
Date:8/1/2011

added.

GT Life Sciences' established business platform for metabolic modeling and engineering of mammalian cells has already proven effective in optimizing CHO cell media and developing novel selectable markers. With the advanced genome sequencing capability of BGI, the CHO-K1 ancestral cell line was sequenced by de novo sequencing and then assembled by BGI's Short Oligonucleotide Analysis Package, SOAPdenovo, resulting in the assembly of 2.45 Gb of the genomic sequence. This information was combined with transcriptome sequence data and led to the generation of 24,383 predicted genes.

"After working with cell culture for over 20 years, this is a dream come true," said Bernhard Palsson, Ph.D., co-founder of GT Life Sciences. "We can now hope to develop metabolic and cell line engineering procedures that approach those currently available for E. coli and yeast. This development signifies the start of genome-scale science for CHO."

"The CHO cell line genome revealed the secret of its protein synthesis, modification and viral resistance, which are very unique among other cell lines and make it the optimal protein production tool," said Xu. Because of the fact that differential glycosylation can substantially affect functional activity and immune responses, researchers carried out a genome-scale assessment of CHO-K1 genes involved in protein glycosylation pathways. They identified homologs to 99% of the human glycosylation-associated genes in the CHO-K1 genome, with 53% of them expressed. The high coverage of homologs provides a unique opportunity for glycoform manipulation in CHO cells. According to the report, the genome of CHO-K1 also provided insight into viral susceptibility genes and found that key genes associated with viral entry are not expressed in CHO-K1.

"Coupling the CHO sequence with a complete genome-scale model of CHO metabolism will prove highly productive in our ability to deliver next-generation process techn
'/>"/>

SOURCE GT Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
2. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
3. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
4. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
5. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
7. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
8. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
9. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
10. Signum Biosciences, Inc. Announces Commercial Launch of Arazineā„¢
11. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... and dosing of patients in its ongoing Phase 2 ... cancer under the revised clinical protocol agreed to with ... form of Halozyme,s proprietary recombinant human hyaluronidase under development ... "Our diligent effort to rapidly re-initiate ...
(Date:7/22/2014)... , July 22, 2014  Neurotrope Bioscience, Inc., a ... world-wide, exclusive license agreement with the Icahn School of ... Mount Sinai ) to utilize its proprietary ... in the treatment of Niemann-Pick Type C Disease (NPC), ... with Alzheimer-like symptoms. The license also covers other diseases ...
(Date:7/22/2014)... BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: ... has appointed Charles J. (Chuck) Bramlage and ... the Board.  Mr. Bramlage is a ... sales and other commercial functions.  He is currently the ... stage company that was recently acquired by AstraZeneca and ...
Breaking Medicine Technology:Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 2BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 4BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 6BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 7
... WOONSOCKET, R.I., Oct. 18, 2011 A recent ... up germs, they are not doing all they can to ... receiving an annual flu shot as recommended by the Centers ... http://photos.prnewswire.com/prnh/20100816/NE50800LOGO) The CDC recommends that anyone ages 6 ...
... With connectivity enabled by Unlimited Systems Interlink integration ... only helps cancer clinics easily meet many of the ... saves time and money by reducing duplicate data entry, ... claims payment and reduced denials. Clinics can ...
Cached Medicine Technology:CVS/pharmacy Survey Reveals Consumer Misconceptions Standing in the Way of Getting a Flu Shot 2CVS/pharmacy Survey Reveals Consumer Misconceptions Standing in the Way of Getting a Flu Shot 3CVS/pharmacy Survey Reveals Consumer Misconceptions Standing in the Way of Getting a Flu Shot 4Navigating Cancer and Unlimited Systems Partner to Provide Cancer Clinics With IT Interoperability to Attain HITECH Act Incentives 2
(Date:7/22/2014)... CA (PRWEB) July 22, 2014 Mona ... instructor certification on August 15th & 16th, 2014, at ... industry's only structured and nationally accredited Bollywood workout was ... Powered by the globally appealing Bollywood culture, Bombay Jam® ... safe, easy to follow and designed with authentic Bollywood ...
(Date:7/22/2014)... IN (PRWEB) July 22, 2014 United ... advisory organization, announces that Les McPhearson, an insurance veteran ... as CEO effective immediately and be based in the ... said, "I am delighted that Les chose to accept ... perfectly qualified to address the many challenges facing UBA ...
(Date:7/22/2014)... The American Society of Hematology (ASH) will honor Tomas ... Los Angeles with the 2014 E. Donnall Thomas Lecture ... discovery of the iron-regulatory hormone hepcidin and investigation of ... the Nobel Prize Laureate and past Society president E. ... that have represented a paradigm shift or significant discovery ...
(Date:7/22/2014)... to heart disease, Dr. Ross Feldman says women are often ... was a men,s-only disease, however, data has shown that post-menopausal ... disease and are less likely to be adequately diagnosed and ... in the British Journal of Clinical Pharmacology brings ... and helps to identify which women are more prone to ...
(Date:7/22/2014)... disorders may share certain pathogenic mechanisms with cancer, according ... researcher Linda Kusner, Ph.D. , published in ... shifting work shows that the very same inhibitors of ... in cells that produce autoimmune diseases. Henry Kaminski, ... the GW School of Medicine and Health Sciences (SMHS), ...
Breaking Medicine News(10 mins):Health News:Mona Khan Company Announces Bombay Jam® Instructor Certification in Los Angeles in August 2014 2Health News:Mona Khan Company Announces Bombay Jam® Instructor Certification in Los Angeles in August 2014 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3Health News:Gene variant identified as a heart disease risk factor for women 2Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2
... the United States via Haiti, probably arriving in just one ... new research. , After the virus, HIV-1, entered the ... results show that the strain of virus that spawned the ... is earlier than a lot of people had imagined," said ...
... born and die without leaving a trace in any ... which to base public health decisions, a University of ... in a paper published today (Oct. 29, 2007) in ... solutions exist to collect these vital statistics and must ...
... prevent or shorten the illness , MONDAY, Oct. 29 (HealthDay ... help prevent pneumonia in elderly nursing home residents, a new ... at 617 people 65 and older in 33 nursing homes ... normal blood zinc concentrations were about 50 percent less likely ...
... Launch National Campaign to Inspire and ... Educate that Prevention is Possible, BERKELEY, Calif., Oct. 29 ... their lifetime. Although 50 percent,of women think breast cancer is hereditary, ... the disease. LUNA, the makers of whole nutrition bars for ...
... produced responses in 40% of patients with Philadelphia, chromosome-positive chronic myeloid ... ... and availability in US means Novartis can offer physicians and ... EAST HANOVER, N.J., Oct. 29 Tasigna(R),(nilotinib) capsules have been approved in ...
... and Los Angeles provide foundation for new education ... and research efforts to fight IPF, ... is pleased to announce that two major fundraising events,hosted in Chicago ... help those suffering from idiopathic pulmonary fibrosis (IPF), a,rare and deadly ...
Cached Medicine News:Health News:HIV's path out of Africa: Haiti, the US then the world 2Health News:HIV's path out of Africa: Haiti, the US then the world 3Health News:Scandal of invisibility plagues countries with no civil registries 2Health News:Scandal of invisibility plagues countries with no civil registries 3Health News:Zinc Helps Elderly Ward Off Pneumonia 2Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 2Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 3Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 2Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 3Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 4Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 5Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 6Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 7Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 8Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 9Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 10Health News:Coalition for Pulmonary Fibrosis Fundraising Events Raise $280,000 for IPF 2Health News:Coalition for Pulmonary Fibrosis Fundraising Events Raise $280,000 for IPF 3
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
A straightforward, versatile approach to arthroscopically assisted pin placement in either the ankle or wrist....
... SureStep Drug Screen Tests are available in ... MDMA (Ecstasy). Designed using Microgenics Antibody Technology, ... only point of care immunoassay targeted to ... both MDA and MDEA but no cross-reactivity ...
Medicine Products: